The pediatric practitioner is often the first point-of-contact for children and adolescents suffering from mental illness. Part of the treatment planning for psychiatric diagnoses includes consideration of medication. Attention-deficit/ hyperactivity disorder, one of the most common diagnoses, is very responsive to stimulant medications; for children who are unable to tolerate stimulants or who do not achieve satisfactory symptom management, central a-agonists and atomoxetine are effective and generally well-tolerated alternative or augmentative agents. Depression and anxiety disorders are also frequently encountered in the pediatric office setting. The use of selective serotonin reuptake inhibitors is considered first-line psychopharmacology for depression and anxiety symptoms. Despite concerns for suicidal ideation related to this medication class, the benefits typically outweigh the risks. This review provides basic clinical pharmacology of stimulant and nonstimulant attention-deficit/hyperactivity disorder medications and selective serotonin reuptake inhibitors intended to serve as a primer for the general pediatrician.
The pediatric practitioner is often the first point-of-contact for children and adolescents suffering from mental illness. Part of the treatment planning for psychiatric diagnoses includes consideration of medication. Attention-deficit/ hyperactivity disorder, one of the most common diagnoses, is very responsive to stimulant medications; for children who are unable to tolerate stimulants or who do not achieve satisfactory symptom management, central a-agonists and atomoxetine are effective and generally well-tolerated alternative or augmentative agents. Depression and anxiety disorders are also frequently encountered in the pediatric office setting. The use of selective serotonin reuptake inhibitors is considered first-line psychopharmacology for depression and anxiety symptoms. Despite concerns for suicidal ideation related to this medication class, the benefits typically outweigh the risks. This review provides basic clinical pharmacology of stimulant and nonstimulant attention-deficit/hyperactivity disorder medications and selective serotonin reuptake inhibitors intended to serve as a primer for the general pediatrician.
Approximately 1 in 5 children in the United States suffers from some form of mental illness, yet 80% of these children do not receive treatment. 1, 2 It is estimated that 75% of children and adolescents with psychiatric disorders are seen in primary care. 3 Furthermore, 7.5% of children and adolescents are prescribed a psychiatric medication, and 85% of psychopharmacologic prescribing is by pediatric providers. 4, 5 Consistent with the American Academy of Pediatrics' (AAP's) mission to enhance pediatric care in a medical home, the AAP charges the following: "Pediatric primary care providers have unique opportunities and a growing sense of responsibility to prevent and address mental health and substance abuse problems in the medical home." 6 The purpose of this review article is to empower primary care pediatricians as basic psychopharmacologists for the common mental health diagnoses of attention-deficit/hyperactivity disorder (ADHD), depression, and anxiety. Mental health care involves an array of interventions, including psychological education, and, contingent on the needs of the child, neuropsychological testing to assess for learning and other comorbid disorders, school accommodations, and psychotherapy. These treatment modalities are important aspects of care but are outside the scope of this article.
ADHD MEDICATIONS Case Vignette
Joey, a 6-year-old, 20-kg boy, presents to his pediatrician, Dr Smith, with complaints of significant hyperactivity, impulsivity, and defiance that are problematic in the classroom and at home. Presentation in the office and parent and teacher Vanderbilt rating scale scores* are consistent with a diagnosis of ADHD, and other medical, psychiatric, and learning issues are ruled out. Dr Smith provides psychological education about ADHD, refers for parent management training, and recommends school accommodations for classroom symptoms. After ensuring no contraindications, he prescribes dexmethylphenidate extended release (ER) (Focalin XR) 5 mg every morning (qAM).
At subsequent weekly or biweekly follow-ups, the dose is titrated to 10, 15, and 20 mg qAM based on parent and teacher Vanderbilt scores demonstrating little or no improvement. At the fourth follow-up, Dr Smith switches to amphetamine/ dextroamphetamine ER (Adderall XR) 20 mg, after which parent and teacher report notable improvement in hyperactivity and impulsivity, although Joey experiences appetite suppression. Dr Smith counsels on high-protein and high-calorie nutrition, but Joey's weight decreases to the point of crossing a weight percentile. The amphetamine/ dextroamphetamine ER dose is decreased to 15 mg then to 10 mg over subsequent visits; although Joey's appetite and weight improve toward baseline, Vanderbilt scores demonstrate return of hyperactivity and impulsivity, although not to the degree of severity of initial presentation. Dr Smith augments amphetamine/dextroamphetamine ER 10 mg qAM with guanfacine ER (Intuniv) 1 mg at bedtime (qHS).
Three weeks later, parent and teacher Vanderbilt scores endorse satisfactory ADHD symptom management, which is maintained through the remainder of the school year, and Joey's weight gain follows an age-appropriate trajectory.
STIMULANTS Indications
ADHD diagnosis and stimulant medication prescription have steadily increased over time. [7] [8] [9] The AAP and the American Academy of Child and Adolescent Psychiatry (AACAP) practice guidelines endorse stimulant medications, methylphenidate and amphetamine, as first-line treatment 10-12 (see Table 1 for effect sizes). Recommendations are robustly evidence based. Specifically, the Multimodal Treatment of ADHD trial showed improvement in inattention, hyperactivity, and impulsivity and amelioration of general disruptive behavior and, to a lesser degree, academic achievement and appropriate peer relations. [13] [14] [15] [16] Off-label prescription indications for stimulant medications include defiance, aggression, depression, and narcolepsy. [17] [18] [19] Prescribing Practice
Before stimulant prescription, the AAP and the American Heart Association recommend careful physical examination and patient and family histories of heart disease, as follows: patient history of palpitations, syncope, or chest pain and family history of sudden death or cardiac disease in children or young adults. 20 Any concerning signs or symptoms warrant cardiac workup before beginning medication. The various formulations of methylphenidates and amphetamines are generally considered to be equally efficacious, although a meta-analysis and more recent randomized controlled trial suggest superiority of lisdexamfetamine over methylphenidates. 21, 22 Amphetamines, however, may have a greater risk of side effects. [23] [24] [25] The Food and Drug Administration (FDA)-approved minimum age for most stimulants is 6 years, with the exception of immediate-release mixed amphetamine salts and dextroamphetamine, both approved to age 3 years. Despite this FDA age approval, methylphenidate was the medication treatment arm selected for use in the landmark Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study, which influenced current clinical practice in preschool-aged children with ADHD. 26 General dosing recommendations favor initiation at the lowest dose and titration as expeditiously as 1-week intervals (see Table 2 for dosing parameters) Long-acting stimulants are generally preferred over short-acting stimulants to minimize dosing frequency. Morning medication should be administered after breakfast. Although some longacting stimulants claim up to 12 hours of medication effect, some children metabolize the medication more quickly, potentially warranting the addition of a short-acting stimulant dose in the afternoon. The Texas Children's Medication Algorithm Project for pharmacotherapy of ADHD advises prescription of a stimulant medication titrated to effect. If response is unsatisfactory, it is recommended that the clinician trial the other stimulant class at an equivalent dose (2 mg methylphenidate to 1 mg dexmethylphenidate to 1 mg amphetamine) titrated to effect. 27 Of note, it is important for pediatricians to discuss the risks of stimulant recreational abuse and diversion with adolescent patients and their families when initiating stimulant medications (see Table 3 for common and serious side effects).
NONSTIMULANT ADHD MEDICATIONS
Although stimulants are first-line treatment of ADHD based on established robust efficacy, there are various indications for the use of FDA-approved nonstimulant medications for children aged $6 years (see Table 1 for effect sizes.) These include failed trials of methylphenidate and amphetamine (secondary to unsatisfactory symptom response at maximum dosage or intolerable side effects), underlying medical conditions lending to greater concern for potential stimulant side effects (including underweight or hypertension), comorbid substance abuse, or family preference. An a-agonist or atomoxetine may be prescribed as monotherapy or, in cases of partial stimulant response, ER clonidine and guanfacine are also FDA-approved as augmentative to stimulant medication.
Indications: Central a 2 -Agonists
Initially indicated for management of hypertension, the central a 2 -agonist medications guanfacine and clonidine are now formulated as ERs (Intuniv and Kapvay, respectively). These are FDA-approved for ADHD treatment in the pediatric population down to age 6 years, and efficacy has been corroborated by a recent metaanalysis. 28 In addition to reduction in distractibility, hyperactivity, and impulsivity, off-label uses include defiance and, with clonidine, sleeponset insomnia. 29
Prescribing Practice: a 2 -Agonists
Because of the antihypertensive effects of guanfacine ER and clonidine ER, strict adherence to prescribing instructions is critical; overdosing could lead to dangerous hypotension and inconsistent dosing might lead to rebound hypertension. Because of potential sedation, it is recommended that dosing initially be at bedtime. Efficacy is observed between 1 and 3 weeks after initiation, and dosing titration may be weekly. Clonidine ER is administered twice daily beginning with the first titration step (see Table 4 for dosing parameters.) When resuming a-agonist medication administration after a period off of medication ($2 days), the dosing should start at the initiation dose and titrated as before. Because abrupt discontinuation of these a-agonists can lead to rebound hypertension, these drugs should be tapered in stepwise intervals weekly until complete discontinuation (see Table 5 for common side effects).
Atomoxetine Indications
Atomoxetine (Strattera) is a norepinephrine reuptake inhibitor medication that is also FDAapproved for use in children and adolescents with ADHD down to age 6 years. A recent positive metaanalysis corroborates efficacy; however, studies suggest that atomoxetine is inferior to stimulants and guanfacine ER. 30 There is evidence for unique benefit in children with comorbid anxiety. As with the aforementioned ADHD medications, there is some medication benefit for defiance. 31 
Prescribing Practice
Atomoxetine is titrated in no sooner than 3 days to the target dose (see Table 4 for dosing parameters.) Twice-daily dosing may be associated with a decrease in defiance and less gastrointestinal side effects. 32, 33 Slower titration is indicated when prescribed concurrently with CYP2D6 inhibitors such as fluoxetine. Medication effect is slower-acting than stimulant and a-agonist medications so families should be advised that it may take 2 to 6 weeks before effects are noticed (see Table 5 for common and serious side effects).
SSRIs Case Vignette
Emma, a 13-year-old girl, presents to Dr Smith with parent complaints of irritability and withdrawal. treatment nonresponse to first-line medication and warrants referral to a child psychiatrist. Once remission has been achieved, patients should be monitored every 3 months, and the medication should be continued for at least 6 to 12 months of stability. 53, 54 When discontinuing the medication, the clinician should slowly taper over a minimum of 1 to 2 months. 56, 57 Abrupt discontinuation may cause flulike symptoms including agitation, dizziness, feeling "spaced out," lightheadedness, drowsiness, poor concentration, nausea, headache, and fatigue. These effects can be reversed by resuming the preceding SSRI dose and tapering at a more gradual rate 57 (see Table 7 for common SSRI side effects).
Safety Risk
After the FDA and UK Medicine Healthcare Products Regulatory Agency released warnings about increased suicidal thoughts and suicidal behaviors among children taking antidepressants, the use of these medications decreased worldwide. 58, 59 The literature calculates the risk of suicidality in children and adolescents taking an SSRI to be low: 1% to 2% of children experience the emergence of suicidal thoughts and behaviors but not completed suicides. 60, 61 The highest risk is seen during the first 9 days of treatment and with higher than usual starting doses. [61] [62] [63] There does not appear to be a significant difference between the various antidepressants despite historical data incriminating paroxetine. 64, 65 The nature of the association between SSRI use and suicidality is unclear. Pediatricians need to be vigilant of the possibility of increased suicidality among patients for whom they are prescribing SSRIs; however, concerns for suicidal ideation are outweighed by the positive, protective effects of an overall decrease in the burden of a High number needed to treat likely secondary to high placebo response rate in pediatric depression studies (30% to 60% compared with 40% to 70% SSRI response rate). SSRI efficacy has been established, but pooled studies and this high number needed to treat underscore the importance of individualizing treatment. disease morbidity and suicide mortality. Informed consent should include the discussion of the relative risk of increased suicidal thinking with antidepressant medications versus the risk of suicide without psychopharmacologic treatment. Consent also includes discussion of the mutually agreed upon threshold for referral to a psychiatric specialist, such as worsening safety concerns, adverse medication reactions that include emergence of mania or psychosis, and lack of response to first-line treatments (see Table 8 for comparison of benefit to suicidality risk 61 ).
CONCLUSIONS
The management of the common diagnoses of ADHD, depression, and anxiety, by way of psychological education, psychotherapy referral, basic psychopharmacology, and appropriate child psychiatry referral, is within the scope of general pediatric practice. Indications for referral include symptoms refractory to first-line treatment, psychotherapy, and aforementioned medications (whether secondary to limiting adverse side effects or to lack of optimal response to maximum dosage) or severe symptoms, including significant and ongoing suicidal ideation or attempt or symptoms of mania or psychosis. 
